Zhang Wuhu, Xu Junfeng, Huang Dan, Qin Yi, Lou Xin, Gao Heli, Ye Zeng, Wang Fei, Wang Yan, Jing Desheng, Fan Guixiong, Zhuo Qifeng, Xin Chang, Chen Jie, Xu Xiaowu, Yu Xianjun, Ji Shunrong
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Center for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai, China.
Oncogene. 2025 Jun 5. doi: 10.1038/s41388-025-03462-5.
High-risk pancreatic neuroendocrine tumors (pNET) are characterized by aggressive progression and metastasis, contributing to poor clinical outcomes. This study explores molecular mechanisms underlying metastasis in high-risk pNETs and evaluates therapeutic interventions. We employed small RNA sequencing to profile miRNA signatures in tumor-derived small extracellular vesicles (sEVs) and integrated single-cell transcriptomic analysis to delineate the tumor immune microenvironment. Prognostic validation of SPP1+ macrophages was performed in clinical cohorts using multiplex immunofluorescence. Mechanistic studies utilized animal models and functional assays to elucidate the sEV-mediated crosstalk between tumor cells and macrophages. Here, we reveal that sEV-miR-183-5p from high-risk pNETs reprograms macrophages via PDCD4/PI3Kγ/AKT/mTOR signaling, inducing SPP1 overexpression and M2 polarization to promote angiogenesis and metastasis. p53 mutants were identified as upstream regulators of sEV-miR-183-5p secretion. Inhibition of SPP1 attenuated tumor progression, while elevated plasma sEV-miR-183-5p levels correlated with high-grade and advanced disease stages. Together, this study reveals a critical sEV-miRNA mediated mechanism governing tumor-macrophage communication in high-risk pNETs, offering insights into therapeutic strategies and suggesting sEV-miR-183-5p may have prognostic potential.
高危胰腺神经内分泌肿瘤(pNET)的特征是侵袭性进展和转移,导致临床预后不良。本研究探讨高危pNET转移的分子机制,并评估治疗干预措施。我们采用小RNA测序来分析肿瘤来源的小细胞外囊泡(sEV)中的miRNA特征,并整合单细胞转录组分析来描绘肿瘤免疫微环境。使用多重免疫荧光在临床队列中对SPP1+巨噬细胞进行预后验证。机制研究利用动物模型和功能试验来阐明sEV介导的肿瘤细胞与巨噬细胞之间的串扰。在此,我们发现高危pNET的sEV-miR-183-5p通过PDCD4/PI3Kγ/AKT/mTOR信号通路对巨噬细胞进行重编程,诱导SPP1过表达和M2极化,以促进血管生成和转移。p53突变体被鉴定为sEV-miR-183-5p分泌的上游调节因子。抑制SPP1可减弱肿瘤进展,而血浆sEV-miR-183-5p水平升高与高级别和晚期疾病阶段相关。总之,本研究揭示了一种关键的sEV-miRNA介导的机制,该机制控制高危pNET中的肿瘤-巨噬细胞通讯,为治疗策略提供了见解,并表明sEV-miR-183-5p可能具有预后潜力。